Effect of low-dose gimeracil and oteracil potassium combined with oxaliplatin on aged patients with advanced gastric cardiac adenocarcinoma

Chinese Journal of Clinical Oncology

Volumn 38, Issue 7, 2011, Pages 396-399

  Chen, Diansen ^a   Jia, Ruinuo ^a   Gao, Shegan ^a   Feng, Xiaoshan ^a   Pan, Lixian ^a   Song, Nasha ^a   Wang, Yufeng ^a   Ding, Kaili ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adverse reaction; Efficacy; Gastric cardic adenocarcinoma; Gimeracil and oteracil potassium capsules; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; GIMERACIL PLUS OTERACIL POTASSIUM; OXALIPLATIN; UNCLASSIFIED DRUG;

ADVANCED GASTRIC CARDIAC ADENOCARCINOMA; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; GERIATRIC PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 79955928532     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2011.07.009     Document Type: Article

References (14)

1. Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)[J]. Ann Oncol, 2010, 21(5): 1001-1005.
2. Lee JJ, Kim SY, Chung HC, et al. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer[J]. Cancer Chemother Pharmacol, 2009, 63(6): 1083-1090.
3. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIR ITS trial): a phase III trial[J]. Cancer Oncol, 2008, 9(3): 215-221.
4. Hataji K, Ami K, Nagahama T, et al. A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent[J]. Gan To Kagaku Ryoho, 2009, 36(12): 2290-2293.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canade [J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
6. Jatoi A, Foster NR, Eqner JR, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trial[J]. Int J Oncol, 2010, 36(3): 601-606.
7. Chrischilles FA, VanGilder R, Wright K, et al. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults[J]. J Am Geriatr Soc, 2009, 57(6): 1000-1006.
8. Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients[J]. Cancer Sci, 2011, 102(2): 478-483.
9. Liu J, Fu XQ, Zhou W, et al. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway[J]. World J Gastroenterol, 2011, 17(2): 181-190.
10. Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin[J]. J Pharm Sci, 2009, 98 (11): 3879-3885.